Advertisement

Topics

Promedior Receives Breakthrough Therapy Designation from FDA for PRM-151 in Idiopathic Pulmonary Fibrosis

11:54 EDT 26 Mar 2019 | Speciality Pharma Journal

LEXINGTON, Mass., March 26, 2019 /PRNewswire/ — Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that PRM-151, a novel investigational anti-fibrotic immunomodulator, has been granted Breakthrough Therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for Idiopathic Pulmonary Fibrosis (IPF).   Promedior recently announced that …

Original Article: Promedior Receives Breakthrough Therapy Designation from FDA for PRM-151 in Idiopathic Pulmonary Fibrosis

NEXT ARTICLE

More From BioPortfolio on "Promedior Receives Breakthrough Therapy Designation from FDA for PRM-151 in Idiopathic Pulmonary Fibrosis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...